Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy using neoantigen-targeted peripheral cells for ATLAS identified anti-tumor antigens that are used to manufacture peripheral blood-derived tumor-specific T cell therapy; and GEN-009, a neoantigen vaccine candidate, delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.
IPO Year: 2014
Exchange: NASDAQ
Website: genocea.com
CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its fourth quarter 2021 financial results and corporate update conference call and live audio webcast on Thursday, March 10th at 8:30 a.m. E.T. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 1066689. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-presentations. A webcast replay will
GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues Strong presence at the SITC 36th Annual Meeting Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today provided a business update for the third quarter ended September 30, 2021. "We continue to make significant progress. Most notably, we are very excited about our TiTAN™ clinical trial for GEN-011, our neoantigen-targeted peripheral T cell therapy (NPT) candidate, from which we expect to have initial data from a small subset of patient
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its third quarter 2021 corporate update conference call and live audio webcast on Thursday, October 28th at 8:30 a.m. E.T. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 8729366. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-presentations. A webcast replay will be available on the Genocea we
CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its second quarter 2021 financial results and corporate update conference call and live audio webcast on Thursday, July 29th at 8:30 a.m. E.T. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 6789021. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-presentations. A webcast replay will be ava
4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)
4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)
4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)
4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)
4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)
4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)
4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)
4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)
4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)
4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)
CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that its Board of Directors voted to wind down the Company's ongoing operations and terminate the Company's remaining employees except those deemed necessary to complete an orderly wind down. On May 23, 2022, the Company delivered formal notice to The Nasdaq Stock Market, Inc. of its intent to voluntarily delist its Common Stock from the Nasdaq Capital Market in connection with the wind down of its operations. The Company plans to file a Form 25 with the Securities and Exchange Commission on or about June 2
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and has engaged professional advisors, including an investment bank to act as a strategic advisor for this process. Strategic alternatives that will be evaluated include the sale of all or part of the Company, merger or reverse merger. As we pursue strategic alternatives, the Company has put into place a restructuring plan which includes an approximate 65% reduction in workforce in the second q
GEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with advanced solid tumors and progressive disease Dose escalation continues toward potentially more effective regimen Initial translational data corroborate clinical findings PLANETTM manufacturing process is highly reliable and continues to improve; patients next to be dosed to receive GEN-011 with substantially boosted yields, neoantigen specificity and potency Investor webcast at 4:30 pm ET today to further discuss data CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation n
CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced details for a planned investor webinar to coincide with the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13. The presentation, beginning at 4:30 PM EDT on Friday, April 8th will be followed by a Q&A session. The Genocea team will discuss previously announced AACR presentations, including late-breaking data from the TiTAN™ clinical trial for the neoantigen-targeted peripheral T cell therapy product candidate GEN-011, and results demonstrating successful pro
CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the 32nd Annual Oppenheimer Healthcare Conference on Thursday, March 17th at 8:40 A.M. ET. A live webcast of the presentation will be available under the "Events and Presentations" tab of the investor relations section of the Genocea website at https://ir.genocea.com/events-presentations. A replay of the webcast will be archived for 90 days following the presentation. About Genocea Biosciences, Inc.Genocea'
Initial GEN-011 clinical trial data to be presented at AACR Conference call today at 8:30 a.m. ET CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today provided a business update for the fourth quarter ended December 31, 2021. GEN-011 TiTAN™ trial update Genocea is conducting the Phase I/2a TiTAN clinical trial for its lead program GEN-011, a neoantigen-targeted peripheral T cell (NPT) therapy candidate. GEN-011 is comprised only of CD8+ and CD4+ T cells, extracted from the patient's peripheral blood and specific for ATLAS-prioritized neoantigens. Pat
Company to present late-breaking clinical trial update for TiTAN trial of GEN-011, Genocea's neoantigen-targeted peripheral T cell therapy for solid tumors The PLANET manufacturing process reliably generates abundant, high-quality neoantigen-specific T cellsPreclinical data indicate that Inhibigens™ accelerate tumor growth in animal models of pancreatic cancer and melanoma CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will present clinical, preclinical, and manufacturing data at next month's American Association for Cancer Research (AACR) Annual Meeting 2
CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that John Lunger, Chief Patient Supply Officer at Adaptimmune Therapeutics plc ("Adaptimmune"), has joined its board of directors. "It is my pleasure to welcome John to our board of directors," said Chip Clark, Genocea's President and Chief Executive Officer. "Scaling our technical operations to ensure the reliable delivery of cost-effective cell therapies is a strategic priority. I am confident John's experiences and expertise will prove invaluable to us on this and many other matters." Mr. Lu
CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its fourth quarter 2021 financial results and corporate update conference call and live audio webcast on Thursday, March 10th at 8:30 a.m. E.T. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 1066689. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-presentations. A webcast replay will
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the virtual 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17th at 10:40 A.M. ET. A live webcast of the presentation will be available in the "Events and Presentations" tab of the investor relations section of the Genocea website at https://ir.genocea.com/events-presentations. A replay of the webcast will be archived for 90 days following the presentation. About Genocea Bioscience
15-12B - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
EFFECT - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
EFFECT - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
POS AM - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
POS AM - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
EFFECT - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
EFFECT - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
POS AM - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
POS AM - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
25 - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)
SVB Leerink reiterated coverage of Genocea Biosciences with a rating of Outperform and set a new price target of $6.00 from $5.00 previously
Needham reiterated coverage of Genocea Biosciences with a rating of Buy and set a new price target of $6.00 from $7.00 previously
SC 13D/A - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)
SC 13G/A - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)
SC 13G/A - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)
SC 13G/A - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)
SC 13G/A - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)
SC 13G - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)
SC 13G/A - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)
SC 13G/A - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)
SC 13G/A - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)
SC 13G/A - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)